NASDAQ:AVXS - AveXis Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$217.83
+0.30 (1.20%)
Get New AveXis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVXS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for AveXis in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $217.83.
N/A
The current consensus among 0 investment analysts is to n/a stock in AveXis. This rating has held steady since April 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/4/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2018Jefferies Financial GroupDowngradeBuy ➝ HoldLow
i
4/13/2018Chardan CapitalDowngradeBuy ➝ NeutralLow
i
Rating by G. Amusa at Chardan Capital
4/12/2018BarclaysDowngradeOverweight ➝ Equal Weight$152.00Low
i
4/12/2018UBS GroupDowngradeBuy ➝ NeutralLow
i
Rating by Carter Gould at UBS Group AG
4/11/2018Credit Suisse GroupReiterated RatingOutperform ➝ Neutral$139.00Low
i
4/10/2018CitigroupDowngradeBuy ➝ NeutralLow
i
Rating by Mohit Bansal at Citigroup Inc.
4/9/2018Nomura SecuritiesUpgradeReduce ➝ NeutralLow
i
4/9/2018Morgan StanleyDowngradeOverweight ➝ HoldN/A
i
Rating by David Lebovitz at Morgan Stanley
4/9/2018Credit Suisse GroupBoost Price TargetOutperform$139.00 ➝ $170.00N/A
i
4/9/2018MizuhoDowngradeBuy ➝ NeutralN/A
i
Rating by Salim Syed at Mizuho
4/9/2018William BlairInitiated CoverageOutperform ➝ HoldN/A
i
Rating by Raju Prasad at William Blair
3/14/2018MizuhoSet Price TargetBuy$147.00High
i
Rating by Salim Syed at Mizuho
3/13/2018William BlairReiterated RatingBuyLow
i
Rating by Raju Prasad at William Blair
3/6/2018Morgan StanleySet Price TargetOverweight ➝ Buy$119.00 ➝ $129.00Medium
i
Rating by David Lebovitz at Morgan Stanley
3/3/2018William BlairReiterated RatingBuyLow
i
Rating by Raju Prasad at William Blair
3/1/2018Jefferies Financial GroupReiterated RatingBuy$141.00High
i
2/28/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$150.00 ➝ $148.00Medium
i
2/28/2018Canaccord GenuitySet Price TargetHold ➝ Hold$110.00 ➝ $120.00Low
i
Rating by Sumant Kulkarni at Canaccord Genuity
2/28/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$134.00 ➝ $139.00Low
i
2/28/2018Wells Fargo & CompanyReiterated RatingOutperform$134.00 ➝ $171.00Low
i
2/28/2018UBS GroupSet Price TargetBuy$122.00 ➝ $143.00Low
i
Rating by Carter Gould at UBS Group AG
2/20/2018Sanford C. BernsteinReiterated RatingOutperform$110.00 ➝ $144.00High
i
2/12/2018MizuhoInitiated CoverageBuy ➝ Buy$147.00Medium
i
2/9/2018BarclaysBoost Price TargetOverweight ➝ Overweight$124.00 ➝ $152.00Medium
i
1/30/2018William BlairReiterated RatingBuyLow
i
Rating by Raju Prasad at William Blair
1/18/2018BMO Capital MarketsReiterated RatingBuy$150.00High
i
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$134.00High
i
1/9/2018Royal Bank of CanadaReiterated RatingHold$92.00Medium
i
1/8/2018BMO Capital MarketsReiterated RatingBuyN/A
i
1/5/2018Canaccord GenuitySet Price TargetHold$110.00High
i
Rating by Sumant Kulkarni at Canaccord Genuity
1/5/2018Chardan CapitalReiterated RatingBuy$135.00High
i
Rating by Gbola Amusa at Chardan Capital
1/5/2018Morgan StanleySet Price TargetBuy$120.00High
i
Rating by David Lebovitz at Morgan Stanley
1/5/2018UBS GroupSet Price TargetBuy$122.00High
i
Rating by Carter Gould at UBS Group AG
1/5/2018CitigroupSet Price TargetPositive ➝ Buy$132.00High
i
Rating by Mohit Bansal at Citigroup Inc.
12/20/2017Canaccord GenuitySet Price TargetHold$110.00Medium
i
Rating by Sumant Kulkarni at Canaccord Genuity
12/14/2017Canaccord GenuitySet Price TargetHold$110.00Low
i
Rating by Sumant Kulkarni at Canaccord Genuity
11/10/2017Bank of AmericaLower Price TargetBuy$115.00 ➝ $112.00N/A
i
11/10/2017Royal Bank of CanadaBoost Price TargetSector Perform ➝ Sector Perform$92.00 ➝ $97.00N/A
i
11/2/2017Royal Bank of CanadaReiterated RatingHold$92.00N/A
i
11/2/2017Chardan CapitalReiterated RatingBuyN/A
i
Rating by Gbola Amusa at Chardan Capital
10/26/2017Canaccord GenuityInitiated CoverageHold ➝ Hold$110.00N/A
i
10/12/2017BMO Capital MarketsReiterated RatingOutperform$123.00 ➝ $130.00N/A
i
10/12/2017Jefferies Financial GroupBoost Price TargetBuy$118.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
10/6/2017The Goldman Sachs GroupReiterated RatingBuy ➝ Buy$130.00N/A
i
10/3/2017UBS GroupReiterated RatingBuy$95.00 ➝ $122.00High
i
10/2/2017CitigroupBoost Price TargetBuy$100.00 ➝ $116.00Low
i
Rating by Mohit Bansal at Citigroup Inc.
9/30/2017BMO Capital MarketsReiterated RatingOutperform$123.00Low
i
9/29/2017Wells Fargo & CompanyReiterated RatingOutperformHigh
i
9/14/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$92.00High
i
9/6/2017BarclaysInitiated CoverageOverweight$124.00Low
i
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform$89.00 ➝ $134.00Low
i
8/29/2017Nomura InstinetInitiated CoverageReduce ➝ Reduce$52.00Low
i
8/28/2017Nomura SecuritiesInitiated CoverageReduce$52.00High
i
8/23/2017William BlairInitiated CoverageOutperform ➝ Outperform$107.00Medium
i
Rating by R. Prasad at William Blair
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$120.00Medium
i
8/11/2017Jefferies Financial GroupReiterated RatingBuy$92.00 ➝ $108.00Low
i
Rating by Biren Amin at Jefferies Financial Group Inc.
8/11/2017Chardan CapitalReiterated RatingBuy ➝ Buy$102.50 ➝ $130.00Medium
i
Rating by Gbola Amusa at Chardan Capital
8/11/2017BMO Capital MarketsReiterated RatingBuy$123.00Medium
i
8/9/2017Morgan StanleyReiterated RatingOverweight$118.00Low
i
8/3/2017Morgan StanleyInitiated CoverageOverweight ➝ Overweight$118.00Low
i
7/27/2017Sanford C. BernsteinInitiated CoverageOutperform$108.00Medium
i
6/28/2017Jefferies Financial GroupReiterated RatingBuyHigh
i
Rating by Biren Amin at Jefferies Financial Group Inc.
6/18/2017Chardan CapitalSet Price TargetBuy$103.00Low
i
Rating by Gbola Amusa at Chardan Capital
6/16/2017BMO Capital MarketsReiterated RatingOutperform$95.00High
i
6/15/2017CitigroupSet Price TargetBuy$90.00 ➝ $100.00Low
i
Rating by Mohit Bansal at Citigroup Inc.
5/25/2017Jefferies Financial GroupReiterated RatingBuy$92.00High
i
Rating by Biren Amin at Jefferies Financial Group Inc.
5/23/2017CitigroupInitiated CoverageBuy$90.00High
i
4/19/2017Jefferies Financial GroupReiterated RatingBuy$92.00Medium
i
Rating by Biren Amin at Jefferies Financial Group Inc.
3/29/2017UBS GroupInitiated CoverageBuy ➝ Buy$95.00N/A
i
3/17/2017Chardan CapitalReiterated RatingBuy$100.00Medium
i
Rating by Gbola Amusa at Chardan Capital
3/17/2017Jefferies Financial GroupBoost Price TargetBuy$79.00 ➝ $92.00High
i
Rating by Biren Amin at Jefferies Financial Group Inc.
3/17/2017The Goldman Sachs GroupBoost Price TargetBuy$91.00 ➝ $108.00High
i
3/17/2017BMO Capital MarketsReiterated RatingOutperform$85.00 ➝ $95.00High
i
2/7/2017Chardan CapitalReiterated RatingBuy$85.00 ➝ $100.00N/A
i
Rating by Gbola Amusa at Chardan Capital
1/26/2017Chardan CapitalBoost Price TargetBuy$85.00 ➝ $100.00N/A
i
Rating by Gbola Amusa at Chardan Capital
12/29/2016BMO Capital MarketsReiterated RatingOutperform$85.00N/A
i
12/25/2016Chardan CapitalSet Price TargetBuy$85.00N/A
i
Rating by Gbola Amusa at Chardan Capital
11/14/2016Jefferies Financial GroupReiterated RatingBuy$71.00 ➝ $79.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
11/14/2016Stifel NicolausInitiated CoverageHold$65.00N/A
i
11/2/2016Chardan CapitalSet Price TargetBuy$65.00 ➝ $85.00N/A
i
Rating by Gbola Amusa at Chardan Capital
11/2/2016Jefferies Financial GroupReiterated RatingBuy$58.00 ➝ $71.00N/A
i
11/2/2016BMO Capital MarketsReiterated RatingOutperform$52.00 ➝ $80.00N/A
i
10/21/2016Bank of AmericaInitiated CoverageBuyN/A
i
10/12/2016Jefferies Financial GroupBoost Price TargetBuy$50.00 ➝ $58.00N/A
i
10/10/2016BMO Capital MarketsReiterated RatingOutperform$52.00N/A
i
9/28/2016Jefferies Financial GroupReiterated RatingBuy$50.00N/A
i
9/19/2016Jefferies Financial GroupBoost Price TargetBuy$42.00 ➝ $50.00N/A
i
8/17/2016Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformN/A
i
8/12/2016Chardan CapitalReiterated RatingBuy$60.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
8/12/2016Jefferies Financial GroupUpgradeHold ➝ Buy$42.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
7/15/2016Wells Fargo & CompanyInitiated CoverageMarket PerformN/A
i
6/22/2016Jefferies Financial GroupDowngradeBuy ➝ Hold$39.00 ➝ $42.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
5/13/2016The Goldman Sachs GroupBoost Price TargetBuy$28.00 ➝ $47.00N/A
i
Rating by Salveen Richter at The Goldman Sachs Group, Inc.
5/9/2016Chardan CapitalReiterated RatingBuy$60.00N/A
i
Rating by Gbola Amusa MD CFA at Chardan Capital
3/28/2016Chardan CapitalInitiated CoverageBuy$60.00N/A
i
3/7/2016The Goldman Sachs GroupInitiated CoverageBuy$28.00N/A
i
3/7/2016Jefferies Financial GroupInitiated CoverageBuy$27.00N/A
i
3/7/2016BMO Capital MarketsInitiated CoverageOutperform$31.00N/A
i
(Data available from 3/6/2016 forward)
AveXis logo
AveXis, Inc., a clinical-stage gene therapy company, engages in developing and commercializing treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its initial product candidate is AVXS-101, a gene therapy product candidate that has completed Phase I clinical trial for the treatment of spinal muscular atrophy Type 1. The company also intends to identify, acquire, develop, and commercialize gene therapy product candidates for the treatment of other rare and life-threatening neurological genetic diseases. It has strategic collaboration and license agreements with Nationwide Children's Hospital; The Research Institute at Nationwide Children's Hospital; REGENXBIO Inc.; and Asklepios Biopharmaceutical, Inc. The company was formerly known as BioLife Cell Bank, Inc. and changed its name to AveXis, Inc. in January 2014. AveXis, Inc. was founded in 2010 and is headquartered in Bannockburn, Illinois.
Read More

Today's Range

Now: $217.83
$217.83
$217.83

50 Day Range

MA: N/A

52 Week Range

Now: $217.83
$65.54
$217.94

Volume

222 shs

Average Volume

816,305 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of AveXis?

The following Wall Street analysts have issued stock ratings on AveXis in the last twelve months:
View the latest analyst ratings for AVXS.

What is the current price target for AveXis?

0 Wall Street analysts have set twelve-month price targets for AveXis in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for AveXis in the next year.
View the latest price targets for AVXS.

What is the current consensus analyst rating for AveXis?

AveXis currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AVXS.

What other companies compete with AveXis?

How do I contact AveXis' investor relations team?

AveXis' physical mailing address is 2275 HALF DAY ROAD SUIT 200, BANNOCKBURN IL, 60015. The company's listed phone number is 847-572-8280 and its investor relations email address is [email protected] The official website for AveXis is www.avexis.com.